

UNIVERSITAT POLITÈCNICA DE VALÈNCIA  
CENTRO DE INVESTIGACION PRINCIPE FELIPE



UNIVERSITAT  
POLITÈCNICA  
DE VALÈNCIA



**DEVELOPMENT OF ANALYTICAL PROCEDURES FOR THE  
CHARACTERIZATION OF POLYPEPTIDE-BASED  
NANOCONJUGATES**

*Doctoral Thesis*  
Snežana Đorđević

*Supervisor*  
Prof. María J. Vicent

*Tutor*  
Prof. Ramon Martínez-Máñez

April 2023

## TABLE OF CONTENTS

---

<b>ABSTRACT .....</b>	<b>9</b>
<b>RESUMEN .....</b>	<b>10</b>
<b>RESUM .....</b>	<b>12</b>
<b>ACKNOWLEDGMENTS .....</b>	<b>14</b>
<b>ZAHVALNICA .....</b>	<b>15</b>
<b>LIST OF ABBREVIATIONS .....</b>	<b>16</b>
<b>OBJECTIVES .....</b>	<b>26</b>

### CHAPTER I

<b>INTRODUCTION .....</b>	<b>28</b>
1.1 Nanomedicine .....	29
1.2 Polymer Therapeutics .....	34
1.3 Rational design of Polypeptide-Drug Conjugates.....	38
1.4 Molecular tale of PDCs, as narrated by analytical chemistry .....	51
1.4.1 Insight into the bioanalysis of PDCs .....	54
1.4.2 The Interaction of PDCs with Biological Constituents .....	55
1.4.3 Pharmacokinetics .....	57
1.4.4 Sample preparation .....	59
1.4.5 Sample analysis .....	60
1.5 Aims .....	63
1.6 Liquid Chromatography- Mass Spectrometry – The gold standard for quantitative and qualitative analyses .....	64
1.6.1 The theoretical principle of LC-MS .....	65
1.7 Design of Experiment – a robust tool for method development ...	67
1.8 Asymmetric-Flow Field-Flow Fractionation – a powerful tool for the physico-chemical characterization of PDCs .....	70
1.8.1 The theoretical principle of AF4.....	76

1.9	Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging .....	78
1.9.1	Mass Spectrometry Imaging .....	79
1.9.2	The theoretical principle of MSI.....	81
1.9.3	MALDI-MSI.....	82

## CHAPTER II

### A ROBUST AND PREDICTIVE PLATFORM FOR THE CHARACTERIZATION OF NEXT-GENERATION POLYPEPTIDE-DRUG NANOCONJUGATES .....88

2.1	Introduction.....	89
2.2	Results.....	90
2.2.1	DoE in LC-MS/MS Method Development for the Quantitative Determination of Fasudil .....	90
2.2.2	Tailor-made LC-MS/MS methods for the quantitative determination of anticancer drugs as a component of PDC characterization studies	104
2.3	Discussion .....	111
2.4	Conclusion .....	113
2.5	Experimental materials and methods .....	114
2.5.1	Materials .....	114
2.5.2	Methods .....	115
2.6	Supplementary material .....	116

## CHAPTER III

### DESIGN OF GENIPIN-ASSEMBLED POLYPEPTIDE-BASED NANOCONJUGATES FOR COMBINATION THERAPY .....129

3.1	Introduction.....	130
3.2	Results.....	134
3.2.1	Evaluating the behavior of PGA within the AF4 separation module... ..	134
3.2.2	DoE implementation in the synthesis of genipin-crosslinked StPGA-based combination conjugates .....	148

3.3	Discussion .....	160
3.4	Conclusions .....	162
3.5	Experimental materials and methods .....	163
3.5.1	Materials .....	163
3.5.2	PDCs synthesis .....	164
3.5.3	Methods .....	165

## CHAPTER IV

### EVALUATING THE BIOLOGICAL FATE AND PHARMACOLOGICAL EFFECT OF PDCs BY MASS

SPECTROMETRY IMAGING.....		<b>168</b>
4.1	Introduction.....	169
4.2	Results.....	172
4.2.1	Synthesis, Characterization, and Evaluation of <i>in vitro</i> Toxicity of Single and Combination PGA-based Conjugates .....	172
4.2.2	Development of a MALDI-MSI Method for Fasudil and Dinaciclib Detection.....	176
4.2.3	Evaluation of Drug Release and Spatial Localization in Spheroids/Mammospheres Following Exposure of MDA-MB-231 TNBC Cells to PDCs.....	182
4.2.4	Metabolic Alterations Induced in 3D TNBC models after Treatment with Single and Combination PDCs .....	188
4.3	Discussion .....	192
4.4	Conclusion .....	196
4.5	Experimental material and methods.....	197
4.5.1	Materials .....	197
4.5.2	PDCs synthesis .....	198
4.5.3	Physicochemical-Characterization of PGA-drug conjugates.....	199
4.5.4	<i>In vitro</i> cell viability assay - MBE embedded spheroids.....	201
4.5.5	<i>In vitro</i> cell viability assay – mammospheres.....	202
4.5.6	Sample embedding.....	202

4.5.7	Sample sectioning and matrix application .....	203
4.5.8	Image acquisition and data processing .....	203
4.5.9	Histological analysis.....	204
4.6	Supplementary material .....	205

## CHAPTER V

### CRITICAL STRATEGIES FOR CRAFTING POLYMER-DRUG CONJUGATES POSSESSING ON-DEMAND DRUG RELEASE .....207

5.1	Introduction.....	208
5.2	Results.....	211
5.2.1	Drug-Et-SS synthesis and their characterization with accurate and robust LC-MS/MS platform .....	211
5.2.2	Drug Release from Individual Drug-Et-SS Depends on Drug Structural Features .....	214
5.2.3	Ph-SS as a Robust Substitute for Et-SS.....	220
5.2.4	Synthesis and Characterization of Polypeptide-based Fasudil Conjugates with Optimized Linkers .....	225
5.2.5	<i>In vitro</i> Anti-Cancer Activity of PDCs Depends on Variables Other Than Drug Release .....	228
5.2.6	Biological Environment and Carrier Architecture as Essential Factors Influencing the Design of Polypeptide-based Drug Conjugates... 238	
5.3	Discussion.....	242
5.4	Conclusion .....	246
5.5	Experimental material and methods.....	248
5.5.1	Materials .....	248
5.5.2	Synthesis and Characterization of Drug-Linkers.....	249
5.5.3	Synthesis and Characterization of PGA-drug conjugates....	249
5.5.4	Drug release from Drug-linkers and PGA-drug conjugates with DTT 251	
5.5.5	Fasudil Release from PGA Conjugates in Cell Medium and MBA-231-TNBC Cells .....	251

5.5.6	Direct mass spectrometry scan .....	252
5.5.7	LC-MS/MS for determination of FAS, DIN, NIRA, RUCA, and RES .....	253
5.5.8	Asymmetric flow field flow fractionation for size determination .....	253
5.5.9	Protocol optimization for fasudil extraction from cell medium .....	254
5.5.10	Cell culture conditions .....	254
5.5.11	<i>In vitro</i> cell viability assay .....	254
5.5.12	GSH/GSSG assay .....	255
5.6	Supplementary Material .....	256

## **CHAPTER VI**

<b>GENERAL DISCUSSION AND FINAL REMARKS .....</b>	<b>268</b>
---	------------

<b>REFERENCES .....</b>	<b>283</b>
-------------------------	------------